Objective: This study aimed to evaluate the ability of luteolin (Lut), gemcitabine (Gem), and their combination (Lut + Gem) to prevent the growth of pancreatic tumors in vivo.
P
ancreatic cancer is the fourth leading cause of cancer-related death for both men and women in the United States, with a 5-year relative survival rate for all stages of only 6%. Of the approximately 46,000 Americans that will be diagnosed with pancreatic cancer in 2014, 40,000 are expected to die with this disease. 1 Currently, the chemotherapeutic drug gemcitabine (Gem) is regarded as the standard of care for patients with pancreatic cancer. 2, 3 However, the development of resistance is a major problem in the use of chemotherapeutic drugs and limits their clinical utility. 4 A key mechanism by which this resistance occurs in pancreatic cancer is through activation of the NF-κB signaling pathway leading to the blockage of apoptosis. 4, 5 Naturally occurring phytochemicals have gained considerable attention as part of a synergistic approach to suppress pancreatic cancer due to their ability to inhibit NF-κB and therefore overcome chemoresistance. 6, 7 Luteolin (Lut), 3′,4′,5,7-tetrahydroxyflavone, is a member of the flavone subclass of flavonoids. It exists abundantly in fruits, vegetables, and herbs such as apples, beets, broccoli, celery, peppers, parsley, and thyme. [8] [9] [10] Previous studies have reported the ability of Lut to inhibit pancreatic cancer cell proliferation in vitro. [11] [12] [13] [14] In addition, we have demonstrated the ability of Lut to enhance the antiproliferative effects of Gem in BxPC-3 pancreatic cancer cells in vitro through inhibition of glycogen synthase kinase-3β (GSK-3β), leading to a decrease in NF-κB transcriptional activity and an increase in apoptosis. 14 Shimasaki et al 15 and Kitano et al 16 showed that inhibition of GSK-3β by its known synthetic inhibitor AR-A014418 in in vitro and in vivo models led to the sensitization of pancreatic cancer cells to Gem. GSK-3β, a serine/threonine protein kinase, has been demonstrated to translocate into the nuclei of pancreatic cancer cells where it stimulates NF-κB transcriptional activity and, as a consequence, promotes the production of antiapoptotic genes. 17, 18 These previous studies suggest that Lut could be useful as an adjuvant to conventional chemotherapies such as Gem through inhibition of the K-ras/GSK-3β/NF-κB signaling pathway; however, in vivo studies are lacking in support of this statement. Our current findings fill that gap.
The objectives were to evaluate the ability of Lut, Gem, and Lut + Gem to prevent the growth of pancreatic tumors using an orthotopic mouse model with injected human pancreatic cancer cells and to investigate the potential mechanism of action related to the K-ras/GSK-3β/NF-κB signaling pathway. The results showed that combination treatment of Lut and Gem promoted apoptotic cell death in pancreatic tumor cells through inhibition of the K-ras/GSK-3β/NF-κB signaling pathway and subsequently a reduction in the bcl-2/bax ratio allowing for the release of cytochrome c from the mitochondria and activation of caspase 3. These findings suggest that Lut + Gem have antitumor activity against pancreatic cancer through inhibition of the GSK-3β/NF-κB signaling pathway, leading to increased apoptosis.
MATERIALS AND METHODS

Materials
The human pancreatic cancer cell line BxPC-3, growth medium Roswell Park Memorial Institute (RPMI) 1640, and 0.25% (w/v) trypsin-0.53 mM ethylenediaminetetraacetic acid were purchased from American Type Culture Collection (ATCC, Manassas, Va). Penicillin-streptomycin was purchased from Corning Inc (Corning, NY) and fetal bovine serum from Hyclone (Thermo Scientific Hyclone, Logan, Utah). Luteolin (≥98%) was purchased from Cayman Chemical (Ann Arbor, Mich) and dissolved in 25% polyethylene glycol 200 (PEG, Sigma-Aldrich, St Louis, Mo). Gemcitabine hydrochloride (>99%) was purchased from Selleck Chemicals (Houston, Tex) and dissolved in PBS (Corning Inc). Primary antibodies for proliferating cell nuclear antigen (PCNA, sc-7907), GSK-3β (sc-9166), P(Tyr216) GSK-3β (sc-135653), P(Ser311)NF-κB p65 (sc-135769), cytochrome c (sc-13560), bax (sc-493), bcl-2 (sc-56018), caspase 3 (sc-56053, sc-7272), and glyceraldehyde 3-phosphate dehydrogenase (sc-47724) were from Santa Cruz Biotechnology, Inc (Santa Cruz, Calif). The primary antibody for K-ras (ab137739) was purchased from Abcam (Cambridge, Mass). ImmunoCruz mouse (sc-2017) and rabbit (sc-2018) ABC staining systems were purchased from Santa Cruz Biotechnology, Inc. Anti-mouse and anti-rabbit IgG horseradish conjugate secondary antibodies were purchased from GE Healthcare Biosciences (Pittsburg, Pa). All other chemicals were purchased from Sigma-Aldrich or Thermo Fisher Scientific Inc (Pittsburgh, PA) unless otherwise stated.
Animals, Care, and Diets
The protocol was approved by the Institute of Animal Care and Use Committee at the University of Illinois at UrbanaChampaign (UIUC). Fifty-two 6-week-old male athymic nude mice were purchased from Harlan Laboratories (Madison, Wis). The mice were housed individually in ventilated wire cages under standardized conditions (21°C, 60% relative humidity, 12-hour light/12-hour dark cycle, 20 air changes/h) at the Institute for Genomic Biology Animal Facility, UIUC. All mice received an irradiated AIN-93G pelleted diet (TD.97184, Harlan Laboratories) and autoclaved drinking water ad libitum throughout the study.
Experimental Design
All mice were acclimated for 1 week before starting the experiments. BxPC-3 human pancreatic cancer cell viability was assessed before injections and was always greater than or equal to 90%. Cells were suspended in PBS at a concentration of 1 million cells per 50 μL PBS and kept on ice until injections. Mice were anesthetized (2.5%-5% isoflurane: air mixture), and the surgical procedure was carried out according to the Institute of Animal Care and Use Committee at the UIUC. Briefly, a small incision on the left side immediately inferior to the rib cage line was made, and the spleen and pancreas were exteriorized. Cells were injected into the pancreas with a 30-gauge needle attached to a 1-mL Hamilton syringe. Both layers of the wound were closed with a wound stapler. Three to 7 days after tumor transplantation, the mice were weighed and randomized into 4 groups as follows: group 1, control group received 100 μL of 25% PEG (vehicle for Lut) by intraperitoneal (IP) injection 7 times/wk for week 1 and 5 times/wk for weeks 2 to 6 (n = 14); group 2, Lut (84 mg/kg body weight [BW]) suspended in 100 μL 25% PEG by IP injection 7 times/wk for week 1 and 5 times/wk for weeks 2 to 6 (n = 12); group 3, 100 μL of 25% PEG by IP injection 7 times/wk for week 1, followed by 100 μL of 25% PEG 5 times/wk, and Gem (125 mg/kg bw) suspended in 100 μL of PBS 2 times/wk (treatments were not on same days) for weeks 2 to 6 (n = 14); and group 4 (Lut + Gem), Lut (84 mg/kg BW) suspended in 100 μL 25% PEG by IP injection 7 times/wk for week 1, followed by Lut (84 mg/kg BW) suspended in 100 μL 25% PEG 5 times/wk, and Gem (125 mg/kg BW) suspended in 100 μL of PBS 2 times/wk (treatments were not on same days) for weeks 2 to 6 (n = 12). The dose of Lut (84 mg/kg BW) was extrapolated from our previous in vitro study, 14 which demonstrated that 15 μM Lut was effective at enhancing the anticancer effects of Gem in BxPC-3 cells. The Gem treatment concentration of 125 mg/kg BW was based on what previous studies using pancreatic cancer xenograft models have shown to be effective. 19 Body weight was recorded twice weekly. Mice were euthanized by carbon dioxide asphyxia after 41 days of treatment. Total BW, pancreas, liver, lung, and spleen weights were determined during necropsy. Each pancreas tumor was divided into 2 pieces as follows: one fixed in 10% neutral buffered formalin solution and the other snap frozen in liquid nitrogen and stored at −80°C. The scheme for the experimental procedures, grouping, and treatment schedule are illustrated in Figure 1 .
Hematoxylin and Eosin Staining of the Pancreas, Spleen, Liver, and Lungs Paraffin-embedded pancreas samples were cut at 5-μm thickness, transferred to slides, and deparaffinized before histologic analysis during standard hematoxylin and eosin (H and E) staining. Stained slides were visualized using NanoZoomer Digital Pathology (Olympus Hamamatsu, Bridgewater, NJ). In addition, 10 mice were randomly selected from each group, and sections of the spleen, liver, and lungs from each were stained with H and E before interpretation in blinded fashion by a board-certified veterinary pathologist. Briefly, formalin-fixed specimens from the spleen, liver, and lungs were trimmed according to a standardized procedure and stored in 70% ethanol until tissue processing. Tissue processing, sectioning, and H and E staining were conducted following the procedures described for the H and E staining of pancreatic tissue. BxPC-3 pancreatic cancer cells into the pancreas. Three to 7 days after surgery, the mice were randomized into 4 groups as follows: control (n = 14), Lut (n = 12), Gem (n = 14), and Lut + Gem (n = 12). The mice were euthanized by carbon dioxide asphyxia after 41 days of treatment.
Immunohistochemical Analyses of Pancreatic Tumor Tissue
Paraffin-embedded pancreatic tissue, normal and tumor, was cut at 5-μm thickness, transferred to a slide, and deparaffinized, and antigen retrieval (K-ras, GSK-3β, P(Tyr216)GSK-3β, and P(Ser311)NF-κB p65 only) was performed using Trisethylenediaminetetraacetic acid buffer before immunohistochemical (IHC) analyses. Immunohistochemical analyses for PCNA, K-ras, GSK-3β, P(Tyr216)GSK-3β, P(Ser311)NF-κB p65, and cytochrome c were performed following the manufacturer's protocol (Santa Cruz Biotechnology, Inc). Stained slides were visualized using NanoZoomer Digital Pathology (Olympus Hamamatsu). The intensity of staining was quantified using Teton machine (MediaCybernetics, Inc, Bethesda, Md) equipped with Axio Vision analysis software (Carl Zeiss, Jena, Germany).
Western Blot Analysis of Pancreatic Tissue
One hundred milligrams of snap frozen pancreatic tissue was mixed with 300 μL of radio-immunoprecipitation assay buffer containing protease cocktail inhibitor, sodium orthovanadate, and phenylmethylsulfonylfluoride (Santa Cruz Biotechnology, Inc). The mixture was homogenized for 1 minute, incubated on ice for 30 minutes, and centrifuged at 10,000 Â g for 10 minutes (4°C), and the supernatants were collected. Protein concentrations were determined using the DC Protein Assay (Bio-Rad Laboratories, Inc, Hercules, Calif). Laemmli buffer containing 5% β-mercaptoethanol was added to the supernatants (1:1); samples were boiled for 5 minutes and then stored at −20°C until use. For Western blot analysis, 100 μg of protein/well was loaded in 4% to 20% gradient SDS-polyacrylamide gels (Bio-Rad Laboratories, Inc). After which, proteins were transferred onto polyvinylidene fluoride membranes (GE Healthcare Biosciences) for 1 hour at 110 V, 4°C. Blocking was performed using 5% nonfat dry milk in 0.1% Tris-buffered saline Tween 20 (TBST) for 1 hour at 4°C. After blocking, the membranes were washed with 0.1% TBST (5 times, 5 minutes each) and incubated with bax, bcl-2, or caspase 3 primary antibodies (1:300) overnight at 4°C. The membranes were washed again and incubated with antimouse or anti-rabbit IgG horseradish peroxidase conjugate secondary antibodies (1:1500) for 1 hour at room temperature. After incubation and repeated washing, the membranes were prepared for detection using a 1:1 mixture of chemiluminescent reagents A (luminol solution) and B (peroxide solution) (GE Healthcare Biosciences). The membrane pictures were taken on a Gel Logic 4000 Pro Imaging System (Carestream Health, Inc, Rochester, NY). The relative amount of each target protein was normalized to glyceraldehyde 3-phosphate dehydrogenase.
Statistical Analysis
GraphPad Prism Software version 4 (La Jolla, Calif) was used. The results were expressed as the mean ± SE, and a nonparametric Mann-Whitney U test was used to test for statistical differences between groups. Significant differences were reported at P < 0.05.
RESULTS
Lut, Gem and Their Combination Modified Mouse BW, Organ Weights, and Pancreatic Mass Table 1 shows the average final BWs, as well as liver, lungs, and spleen weights in relation to final BW among the groups after 41 days of treatment. Gem and Lut + Gem groups had significant changes in BW compared with the control (P = 0.012 and P = 0.002, respectively), whereas Lut treatment alone did not (P = 0.227). There were no significant differences in mean lungs weights as compared with the control. However, the Gem-treated group had a significantly lower (P = 0.045) mean liver weight than the control group, and groups treated with either Lut alone or in combination with Gem had significantly higher mean spleen weights (P = 0.025 or 0.010, respectively) compared with the control group.
Mean pancreas weight (g) over BW (g) ( Fig. 2A ) was 0.021 in the Lut group and 0.014 in the Gem group; however, only Lut + Gem group, with a mass of 0.013, was significantly lower (P = 0.048) than the control group mass of 0.027. Subtracting the normal pancreas weight/BW in each group from all previous numbers resulted in values of 0.022 for the control group, 0.016 for the Lut group (P = 0.777, compared with control), 0.009 for the Gem group (P = 0.078, compared with control), and 0.008 for the Lut + Gem group (P = 0.048, compared with control). If the net pancreas weights were compared, without considering the BW, the results were 0.829 g for control group, 0.631 g for All values are shown as mean ± SE. *To account for differences in BW of the mice, liver, lung, and spleen weights were divided by individual BWs to get a ratio. † Treatment groups were individually compared with the control group for each type of weight. ‡ Groups that were statistically different as determined by Mann-Whitney U analysis.
Lut group (P = 0.681, compared with control), 0.376 g for Gem group (P = 0.016, compared with control), and 0.337 g for Lut + Gem group (P = 0.013, compared with control). In this case, the weight of pancreas for Gem and Lut + Gem was statistically different from the control. Three representatives of pancreatic histology from each group are presented in Figure 2B .
Hematoxylin and Eosin Staining Results of the Pancreas, Spleen, Liver, and Lungs Figure 3A shows representative slides of H and E staining of pancreas sections from each treatment group. (Supplemental Digital Content, Table 1 , http://links.lww.com/MPA/A327). presents the H and E staining results (n = 10) of spleen, liver, and lungs to determine the metastasis of the cancer and potentially undesirable effects due to treatment. The highest metastasis was to the spleen, 3 of 10 for control group, 2 of 10 for Lut, and 4 of 10 for Lut + Gem group, but no spread to the spleen was found in the Gem group. Metastasis to the liver was found in the control (2/10), Lut (1/10), and Lut + Gem (1/10) groups, but no spread to the liver was found in the Gem group. There was no metastasis to the lungs in any treatment group. There were also no undesirable effects related to treatment found in the lungs or liver of mice in any treatment group. However, capsular fibrosis was found in the spleens of mice in the control group (1/10), Lut group (4/ 10), Gem group (1/10), and Lut + Gem group (3/10). Figure 3B shows the effect of Lut, Gem, and Lut + Gem on the expression of PCNA in pancreatic tumor tissue. All 3 treatments caused a significant reduction in PCNA expression with Lut causing a 25% reduction (P = 0.005), Gem causing a 37% reduction (P = 0.0002), and Lut + Gem causing a 37% reduction (P = 0.0008).
Lut, Gem, and Their Combination Reduced the Expression of Proliferating Cell Nuclear Antigen
Combination Treatment of Lut and Gem Decreased the Expressions of K-ras, GSK-3β, P(Tyr216)GSK-3β, and P(Ser311)NF-κB p65 in Pancreatic Tumor Tissue Figure 4 displays the effect of Lut, Gem, and Lut + Gem in pancreatic tumor tissue on the expression of K-ras, GSK-3β, P (Tyr216)GSK-3β (active form), and P(Ser311)NF-κB p65 (active form). In Figure 4A , single-agent Lut and Gem treatments resulted in nonsignificant effects in the expression of K-ras (upstream GSK-3β effector) of 20% (P = 0.122) and 16% (P = 0.293), respectively, whereas Lut + Gem treatment resulted in a significant reduction of 46% (P = 0.0006). In Figure 4B , Lut and Gem treatments resulted in nonsignificant effects in the expression of GSK-3β of 8% (P = 0.762) and 17% (P = 0.593), respectively, whereas Lut + Gem treatment resulted in a significant reduction of 34% (P = 0.0014). In Figure 4C , Lut and Gem treatments resulted in nonsignificant effects in the expression of P(Tyr216) GSK-3β of 10% (P = 0.261) and 8% (P = 0.174), respectively, whereas Lut + Gem treatment resulted in a significant reduction of 16% (P = 0.033). In Figure 4D , Lut and Gem treatments resulted in nonsignificant decreases in the expression of P(Ser311)NF-κB p65 of 12% (P = 0.418) and 11% (P = 0.503), respectively, whereas Lut + Gem treatment resulted in a significant reduction of 27% (P = 0.036). Immunohistochemical staining of the surrounding normal pancreatic tissues showed that there was no a significant effect of treatment on the expression of K-ras, GSK-3β, and P(Tyr216)GSK-3β among the 4 groups (Supplemental Digital Content, Fig. 1 , http://links.lww.com/MPA/A328). In addition, significant reduction of P(Ser311)NF-κB p65 in the 3 treatment groups was observed when each group was compared with the control group.
Lut, Gem, and Their Combination Modified the Expression of Proteins Involved in Apoptosis in
Pancreatic Tumor Tissue Figure 5 shows the effect of Lut, Gem, and Lut + Gem on the expression of the apoptotic marker cytochrome c. Figure 6 shows the effect on the bcl-2/bax ratio and on caspase 3 in pancreatic tissue. As shown in Figure 5 Lut + Gem treatment resulted in a significant increase (P = 0.035) in cytochrome c expression of 44% as measured by IHC staining of pancreatic tumor tissue. Taking into account the expressions of bcl-2/bax ratio, Gem treatment resulted in a significant reduction from 1.00 (control group) to 0.34 (P = 0.022), whereas Lut + Gem reduced this ratio to 0.32 (P = 0.006) (Fig. 6A) . On the other hand, Lut treatment alone did not affect the bcl-2/bax ratio (P = 0.960). The reduction in the bcl-2/bax ratio allowed for activation of the executioner of apoptosis, caspase 3, as shown by a statistically significant increase in its expression in the Lut + Gem group by 417% (Fig. 6B , P = 0.003) when compared with the control group.
DISCUSSION
Luteolin has been reported to exhibit anticancer effects in various cancer cells as well as to potentiate the cytotoxic effects of celecoxib in breast cancer cells, 20 of oxaliplatin, bleomycin, and doxorubicin in lung cancer cells, 21 and cisplatin in leukemia cells. 22 However, the effect of Lut against pancreatic cancer cells in vitro has only recently began to be investigated, [11] [12] [13] [14] and an in vivo study on its effects on pancreatic cancer has yet to be published.The present study examined the ability of Lut, Gem, and their combination to prevent the growth of pancreatic tumors in an orthotopic mouse model. In this study, Lut and Gem were not administered on the same day based on our previous in vitro study, FIGURE 4 . Inhibitory effect of Lut, Gem, and their combination on the expression of K-ras, GSK-3β, P(Tyr216)GSK-3β, and P(Ser311)NF-κB p65. A, Immunohistochemical staining for K-ras in pancreatic tumor tissue showed that combination treatment of Lut and Gem resulted in a significant (indicated by the asterisk) reduction in its expression when compared with the control group as determined by Mann-Whitney U analysis (n = 6). B, Combination treatment of Lut and Gem significantly (*) reduced the expression of GSK-3β in pancreatic tumor tissue compared with the control group as determined by Mann-Whitney U analysis (n = 5). C, Combination treatment of Lut and Gem significantly (*) reduced the expression of P(Tyr216)GSK-3β in pancreatic tumor tissue compared with the control group as determined by Mann-Whitney U analysis (n = 6). D, Combination treatment of Lut and Gem significantly (*) reduced the expression of P(Ser311)NF-κB p65 in pancreatic tumor tissue compared with the control group as determined by Mann-Whitney U analysis (n = 5). Values are presented as mean ± SE. P < 0.05 indicates significant differences. On the basis of the IHC peroxidase staining assay, the color produced was brown. Editor's note: A color image accompanies the online version of this article.
which showed that simultaneous treatment of Lut with chemotherapeutic drugs produced less than additive effects. 14 The results of this study showed that combination treatment of Lut and Gem was able to significantly lower pancreatic mass compared with the control group, when mean pancreas weight over mean BW was considered. Although a statistically significant difference was found, in this case, only between the control and Lut + Gem group, a nonsignificant difference in therapeutic effect was found between Gem and Lut + Gem groups. However, if the net pancreas weights were compared, without considering the animal BW, Gem and Lut + Gem were statistically different from the control. There is a need to optimize the dose and time of exposure to Lut to produce a significant impact and no toxicity.
Spleen weights were most likely affected by capsular fibrosis and metastasis. Splenic capsular fibrosis can occur in association with inflammatory, toxic, or neoplastic lesions. It is uncertain whether the fibrosis was caused by the cancer or due to potential toxicity caused by treatment. The difference in mean liver weights could be explained by the lack of metastasis in the Gem group.
PCNA expression is associated with the late G1 and S phases of the cell cycle. 23 Its significance as a measure of tumor growth and metastasis has been investigated in pancreatic cancer. For instance, strong expression of PCNA was reported in cell lineinduced pancreatic tumors in rats, 24 whereas suppression of PCNA oncogenic activity is associated with development of novel drug therapy for pancreatic cancer. 25 The results showed that expression of PCNA was significantly reduced by all treatments indicating that Lut, Gem, and Lut + Gem have the capability to reduce proliferation of pancreatic cancer in vivo. This was further supported by the observation that these groups had lower pancreatic tumor burden as compared with the control group. When compared with the control group, the P value of the Gem group (0.002) was slightly smaller than that of the Lut + Gem group (0.008) and not significantly different statistically.
Inhibition of cell proliferation and/or induction of apoptosis are 2 major mechanisms by which cancer cells are killed by chemotherapeutic agents. Unfortunately, resistance to apoptosis induced by chemotherapeutic agents, including Gem, constitutes a major obstacle in the use of these drugs for pancreatic cancer treatment. 26 Several studies have shown that inhibition of a key target, NF-κB, in cancer pathogenesis by novel bioactive compounds leads to the sensitization of pancreatic cancer cells to chemotherapeutic drugs. [27] [28] [29] In the present study, the combination treatment of Lut and Gem caused a significant decrease in GSK-3β, P (Tyr216)GSK-3β (active form), and NF-κB [as measured by a decrease in the active form of p65 subunit, P(Ser311)NF-κB p65], as well as an increase in apoptosis, specifically the mitochondrial pathway of apoptosis. Activation of this pathway of apoptosis causes the release of cytochrome c from the mitochondria allowing for the formation of the apoptosome multiprotein complex, which activates caspase 9 and in turn leads to the cleavage of caspase 3, the executioner of apoptosis. 30 The results indicated that combination treatment of Lut and Gem led to the release of cytochrome c from the mitochondria and therefore the activation of caspase 3 through a reduction in the bcl-2/bax ratio, regulators . Effect of Lut, Gem, and their combination on the expression of bax, bcl-2, and caspase 3 in pancreatic tumor tissues as evaluated by Western blot. Protein lysates from pancreatic tissue were extracted and subjected to Western blot analysis for bax, bcl-2, and caspase 3 protein expressions. A, Treatment with Gem or the combination of Lut and Gem significantly (*) decreased the bcl-2/bax ratio compared with the control group as determined by Mann-Whitney U analysis (n ≥ 4). B, Combination treatment of Lut and Gem significantly (*) increased the expression of proapoptotic caspase 3 compared with the control group as determined by Mann-Whitney U analysis (n ≥ 6). Values are presented as mean ± SE. P < 0.05 indicates significant differences.
of mitochondrial membrane permeability. This suggests that Lut can be used in combination with Gem in promoting apoptosis of pancreatic cancer in vivo.
K-ras is an oncogene that is found to be mutated in up to 90% of diagnosed pancreatic tumors. 31 Zhang et al 32 suggested that K-ras increases GSK-3β gene expression via the mitogen-activated protein kinases signaling pathway in pancreatic cancer cells. Although K-ras is not found to be mutated in the BxPC-3 cell line 33 used in the present in vivo study, combination treatment of Lut and Gem did lead to a significant reduction in K-ras expression, and this could potentially explain the reduction in GSK-3β expression. We have previously demonstrated the ability of apigenin, a flavonoid that differs from Lut by 1 hydroxyl group, to inhibit K-ras expression in both BxPC-3 (wildtype K-ras, grade 2 primary pancreatic ductal adenocarcinoma) and PANC-1 (mutated K-ras, 34 grade 3 primary pancreatic ductal adenocarcinoma) pancreatic cancer cells in vitro. 13 Due to significantly lower flavonoid concentrations needed to provide an anticancer effect in vitro, the BxPC-3 cell line was chosen for this in vivo study. Luteolin also has the potential to inhibit mutated K-ras, but more studies are needed to determine the mechanism of action.
Chemotherapeutic drugs often cause various adverse effects in patients, including anorexia, constipation, or diarrhea, which can cause undernourishment and loss of BW. We found that the final BW of mice treated with Gem alone or in combination with Lut was significantly less than the control or Lut groups. Wei et al 35 also reported a significant BW loss at the end of their study compared with the control group when 125 mg/kg BW Gem was used in a pancreatic cancer xenograft model. However, they reported that combination treatment of evodiamine (a bioactive compound in Evodiae fructus) and a lower dose of Gem (80 mg/kg BW) was able to effectively inhibit pancreatic tumor growth without leading to a significant BW loss. Although the negative adverse effects associated with using Gem for chemotherapy are extensively known, the negative adverse effects associated with using Lut as a treatment have yet to be determined. Capsular fibrosis found in the spleens of mice treated with Lut may have been caused by toxicity due to treatment or localized trauma associated with the initial surgery and injection of cancer cells although such a response also may have been due to a stromal reaction to nearby malignant neoplastic tissue.
In the present study, an orthotopic mouse model of pancreatic cancer was used to determine the effects of Lut, Gem, and their combination in inhibiting tumor growth. In an orthotopic model of pancreatic cancer, the tumor cells are implanted directly into the pancreas, mimicking tumor microenvironment, and are therefore deemed to more closely resemble the natural tumorigenesis in humans. 36 Collectively, the present study demonstrated the potential of Lut to be used in combination with Gem in preventing the growth of pancreatic cancer in an orthotopic mouse model. Combination treatment of Lut and Gem promoted apoptotic cell death in pancreatic tumor cells through inhibition of the K-ras/GSK-3β/ NF-κB signaling pathway and subsequently a reduction in the bcl-2/bax ratio allowing for the release of cytochrome c from the mitochondria and activation of caspase 3.
The average current daily consumption of flavonoids for humans is 132 mg/d, and of that, 1 mg/d is from flavones. 37 However, in this study, a Lut dose of 84 mg/kg BW was given by IP injection to mice, and this dose was not intended to provide information on the use of this compound as a dietary agent in pancreatic cancer. If the dose in this study was translated up to a 70-kg human, a human would have to consume 5.9 g of Lut, which is about 45 times the average amount of flavonoids currently consumed daily. It would be almost impossible to reach that amount through fruit and vegetable consumption. The use of nanoparticles to encapsulate Lut, allowing it to be administered orally, while improving its low bioavailability 38 would be an interesting and important area to explore. In addition, it is currently undetermined whether 5.9 g of Lut would even be tolerated in humans when orally administered. A human study has demonstrated oral tolerance with a dosage of 8 g/d of the polyphenol curcumin, 39 suggesting potential oral tolerability for Lut, and studies are underway to investigate the maximal tolerable dose of Lut for humans. Furthermore, more studies are needed to determine the maximum dose of Lut that can be used before toxicity occurs and the specific potential negative effects that might occur due to Lut toxicity.
